PHI预测不良病理与PHI密度预测升级:局限期前列腺癌的两个互补预测因子
前瞻性单中心观察研究纳入130例接受机器人辅助根治性前列腺切除术的局限期前列腺癌患者,评估PHI与PHI密度(PHId)对不良病理特征及ISUP升级的预测能力。PHI是不良病理的最强独立预测因子(OR 1.04,95%CI 1.02-1.07,AUC 0.86),PHId是唯一与升级独立相关的标志物(OR 1.54,95%CI 1.10-2.29,AUC 0.83)。两者提供互补信息,整合入评估可能支持精准决策。
要点
- PHI独立预测不良病理特征(pT≥3和/或pN1),模型AUC达0.86。
- PHId是唯一独立预测活检至根治术ISUP升级的标志物,AUC 0.83。
- PHI>40时不良病理风险急剧增加,PI-RADS 4-5患者PHId升级风险更明显。
核心结论
- PHI与PHId在局限期前列腺癌中提供互补信息,PHI准确识别不良病理延伸风险,PHId有效捕捉根治术时分级重分类概率。
研究设计与样本
- 前瞻性单中心观察研究,纳入130例接受机器人辅助根治性前列腺切除术的患者。
- 使用Access 2平台测定总PSA、游离PSA和p2PSA,计算PHI和PHId。
- 多变量逻辑回归模型评估PSA、PSA密度、PHI和PHId与两个预设终点的关联,并校正DRE状态、PI-RADS评分和活检ISUP分级。
主要发现
- 中位PSA为6.21 ng/mL,中位PHI为58,中位PSA密度为0.15 ng/mL/cc,中位PHId为1.40。
- 39%的病例发现不良病理特征,59%的病例发生升级(排除活检ISUP 5病例后)。
- PHI是不良病理的最强独立预测因子(OR 1.04;95%CI 1.02-1.07),模型准确度最高(AUC 0.86),PHI>40时风险急剧增加。
- PHId是唯一与升级独立相关的标志物(OR 1.54;95%CI 1.10-2.29),区分度最佳(AUC 0.83),在PI-RADS 4-5病变患者中风险升高尤为明显。
临床怎么用
- 可将PHI用于术前评估不良病理延伸风险,辅助识别可能受益于更广泛手术或辅助治疗的患者。
- 可将PHId用于评估活检至根治术分级升级概率,尤其在PI-RADS 4-5病变患者中,以支持精准决策并减少治疗不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Prostate Health Index (PHI) has emerged as a promising biomarker for improving prostate cancer (PCa) detection. However, its role in predicting pathological aggressiveness at radical prostatectomy (RP) requires further elucidation. We aimed to assess the ability of PHI and PHI density (PHId) to predict adverse pathological features and ISUP upgrading in men undergoing robot-assisted RP. METHODS: We conducted a prospective, single-center observational study including 130 patients who underwent RP. Total PSA, free PSA, and p2PSA were measured using the Access 2 platform, and PHI and PHId were calculated accordingly. Multivariable logistic regression models evaluated the association of PSA, PSA density, PHI, and PHId with two predefined endpoints: (i) adverse pathological features (pT ≥3 and/or pN1), and (ii) upgrading from biopsy to RP. Models were adjusted for DRE status, PI-RADS score, and biopsy ISUP grade. Discrimination was assessed using AUC and the DeLong test. RESULTS: Median PSA, PHI, PSA density, and PHId were 6.21 ng/mL, 58, 0.15 ng/mL/cc, and 1.40, respectively. Adverse pathological features were identified in 39% of cases, and upgrading occurred in 59% (after exclusion of biopsy ISUP 5 cases). PHI emerged as the strongest independent predictor of adverse pathology (OR 1.04; 95% CI 1.02-1.07), yielding the highest model accuracy (AUC 0.86) and showing a sharp risk increase above PHI > 40. PHId was the only marker independently associated with upgrading (OR 1.54; 95% CI 1.10-2.29), achieving the best discrimination (AUC 0.83), with risk escalation particularly evident in patients with PI-RADS 4-5 lesions. CONCLUSIONS: PHI and PHId provide complementary information in localized PCa. PHI accurately identifies patients at risk of adverse pathological extension, whereas PHId effectively captures the probability of grade reclassification at RP. Integrating these biomarkers into patient assessment may support precision-based decision-making and helping to minimize undertreatment.
引用
- Terracciano D, Pellegrino F, Fiorenza M, et al. PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 42778618. doi:10.1038/s41391-026-01158-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。